reglab/statecodes huggingface dataset:
Oklahoma Administrative Code › Title 475 - Oklahoma State Bureau of Narcotics and Dangerous Drugs Control › Chapter 25 - Records and Reports of Registrants › Section 475:25-1-16 - Records of scientific researchers

Current through Vol. 41, No. 20, July 1, 2024
Each person registered or otherwise authorized to conduct
						scientific research with controlled dangerous substances and required to keep
						records shall maintain records with the following information for each
						controlled dangerous substance:
(1) The
					name of the substance.
(2) Each
					finished form (e.g., 10-milligram tablet or 10-milligram concentration per
					fluid ounce or milliliter) and the number of units or volume of finished form
					in each commercial container (e.g., 100-tablet bottle or 3-milliliter vial).
(3) The number of commercial
					containers of each such finished form received from other persons, including
					the date of and number of containers in each receipt and the name, address,
					and, if applicable, Federal Drug Enforcement Administration registration number
					of the person from whom the containers were received.
(4) The number of units or volume of such
					finished forms and/or commercial containers disposed of in any other manner by
					the registrant, including the date and manner of disposal and the quantity of
					the substance in the finished form disposed.
Oklahoma Administrative Code › Title 475 - Oklahoma State Bureau of Narcotics and Dangerous Drugs Control › Chapter 25 - Records and Reports of Registrants › Section 475:25-1-17 - Records of analytical laboratory activities

Current through Vol. 41, No. 20, July 1, 2024
(a) Each person registered or otherwise
					authorized to conduct analytical laboratory activites with controlled dangerous
					substances shall maintain records with the following information to the extent
					known and reasonably ascertainable by him/her for each controlled dangerous
					substance:
(1) The name of the
					substance.
(2) The form or forms in
					which the substance is received, imported, or manufactured by the registrant
					(e.g., powder, granulation, tablet, capsule, or solution) and the concentration
					of the substance in such form (e.g., C.P., U.S.P., N.D., 10-milligram tablet or
					10-milligram concentration per milliliter).
(3) The total number of the forms received,
					imported, or manufactured (e.g., 100 tablets, 30 1-milliliter vials, or 10
					grams of powder), including the date and quantity of each receipt, importation
					or manufacture, and the name, address, and Federal Drug Enforcement
					Administration registration number, if any, of the person from whom the
					substance was received.
(4) The
					quantity distributed or destroyed in any manner by the registrant (except
					quantities used in chemical analysis or other laboratory work), including the
					date and manner of distribution or destruction and the name, address, and
					Federal Drug Enforcement Administration registration number, if any, of each
					person to whom the substance was distributed.
Oklahoma Administrative Code › Title 475 - Oklahoma State Bureau of Narcotics and Dangerous Drugs Control › Chapter 25 - Records and Reports of Registrants › Section 475:25-1-18 - Records of medical institutions

Current through Vol. 41, No. 20, July 1, 2024
Each registered medical institution licensed by the Oklahoma
						State Department of Health or the Oklahoma State Department of Human Services
						as a hospital or otherwise authorized to professionally handle controlled
						dangerous substances shall maintain records with the following information for
						each controlled dangerous substance:
(1) Each such registered or otherwise
					authorized hospital shall issue a specific internal code number for each
					resident or staff practitioner required within the scope of his or her
					employment to administer, dispense or prescribe controlled dangerous substances
					within the hospital. The code number shall consist of numbers, letters, or a
					combination thereof, and shall be a suffix to the hospital's Federal Drug
					Enforcement Administration registration number, preceded by a hyphen (e.g.,
					AB1234567-12 or AB1234567-A12).
(A) If the
					hospital has a graduate intern training program authorized by the Oklahoma
					State Board of Medical Licensure and Supervision, the hospital may authorize
					such interns, required within the scope of his or her employment, to
					administer, dispense or prescribe controlled dangerous substances within the
					hospital, in accordance with
					475:10-1-5.
(B) A current list of the internal code
					numbers of each hospital and the corresponding authorized individual resident,
					staff practitioner or intern shall be kept by the hospital pharmacist and will
					be made available at all times to other registrants and properly designated law
					enforcement agencies upon request, for the purpose of verifying the prescribing
					individual practitioner.
Oklahoma Administrative Code › Title 475 - Oklahoma State Bureau of Narcotics and Dangerous Drugs Control › Chapter 25 - Records and Reports of Registrants › Section 475:25-1-19 - Order forms

Current through Vol. 41, No. 20, July 1, 2024
Procedures governing the issuance, use and preservation of
						order forms regarding controlled dangerous substances shall be maintained
						pursuant to Title 21 Code of Federal Regulations §1305 in accordance with
						Title 63 Okl.St.Ann. §2-308 .
Oklahoma Administrative Code › Title 475 - Oklahoma State Bureau of Narcotics and Dangerous Drugs Control › Chapter 25 - Records and Reports of Registrants › Section 475:25-1-20 - Reports for manufacturers and distributors

Current through Vol. 41, No. 20, July 1, 2024
(a) Except Schedule I medical marijuana registrants, manufacturers required to register pursuant to Title 63 Okla.St.Ann  §
								2-302   shall provide the following data on every sale of any controlled dangerous substance in Schedules I, II, III, IV, and V.
(1) The manufacturer's or distributor's name, address, phone number, DEA registration number and controlled dangerous substance registration number issued by the Bureau;
(2) The name, address and DEA registration number of the entity to whom the controlled dangerous substance was sold;
(3) The date of the sale of the controlled dangerous substance
(4) The name and National Drug Code of the controlled dangerous substance sold; and
(5) The number of containers and the strength and quantity of controlled dangerous substances in each container sold.
Oklahoma Administrative Code › Title 475 - Oklahoma State Bureau of Narcotics and Dangerous Drugs Control › Chapter 30 - Labeling Requirements › Section 475:30-1-1 - Purpose

Current through Vol. 41, No. 20, July 1, 2024
The rules of this Chapter describe the procedures to be
						followed for issuance of a valid prescription, and the information required to
						be placed on labels for controlled dangerous substances. Labeling for Schedule
						I medical marijuana shall be in accordance with OAC 310:681-7-1.
Oklahoma Administrative Code › Title 475 - Oklahoma State Bureau of Narcotics and Dangerous Drugs Control › Chapter 30 - Labeling Requirements › Section 475:30-1-2 - Persons entitled to issue prescriptions

Current through Vol. 41, No. 20, July 1, 2024
Only a registered individual practitioner may issue a prescription for a Schedule II, III, IV and V controlled dangerous substance. Except as otherwise prohibited by law or rule, an individual practitioner, an authorized employee of the practitioner, or an authorized employee of the facility at which the practitioner works may communicate by telephone an oral prescription for any controlled dangerous substance in Schedules III, IV or V being prescribed by the individual practitioner. It remains the responsibility of the practitioner to guard against the diversion of CDS by employees authorized by him/her to call in such prescriptions.
Amended at 12 Ok Reg 2847,
						eff 7-15-95; Amended at 24 Ok Reg 2741, eff
						8-11-07
Oklahoma Administrative Code › Title 475 - Oklahoma State Bureau of Narcotics and Dangerous Drugs Control › Chapter 30 - Labeling Requirements › Section 475:30-1-3 - Purpose of issuance of prescriptions

Current through Vol. 41, No. 20, July 1, 2024
(a) A prescription for a controlled dangerous
					substance to be effective must be issued for a legitimate medical purpose by a
					registered or otherwise authorized individual practitioner acting in the usual
					course of his/her professional practice. The responsibility for the proper
					prescribing and dispensing of controlled dangerous substances is upon the
					prescribing practitioner, but a corresponding responsibility rests with the
					pharmacist who fills the prescription, as the filling of a prescription is not
					incumbent on the pharmacy. An order purporting to be a prescription issued not
					in the usual course of professional treatment or in legitimate and authorized
					research is not a prescription within the meaning and intent of Title 63
					Okl.St.Ann. §§2-309 and 2-312, and the person knowingly filling such
					a purported prescription, as well as the person issuing it, shall be subject to
					the penalties provided for violations of the provisions of law relating to
					controlled dangerous substances.
(b) A prescription may not be issued in order
					for a registered or otherwise authorized individual practitioner to obtain
					controlled dangerous substances to stock or re-supply his/her office or medical
					bag for the purpose of general dispensing to patients. Such orders for stock or
					re-supply must be made by invoice for schedules III, IV, and V, or by DEA-222
					order form for schedules I and II.
(c) A prescription may not be issued for the
					dispensing of a controlled dangerous substance listed in any schedule to a drug
					dependent person for the sole purpose of continuing his/her dependence upon
					such drugs. This prohibition applies to the use of gradually diminished doses
					for the purpose of tapering the person's dependence. This section does not
					apply to a properly licensed and registered narcotic treatment
					program.
(d) A practitioner may not
					distribute, dispense, sell, give, prescribe or administer any controlled
					substances in Schedules I through V for the practitioner's personal use, or for
					an immediate family member. Provided that this paragraph shall not apply to
					family members outside the second degree of consanguinity or affinity. Provided
					further that this paragraph shall not apply to medical emergencies when no
					other medical doctor is available to respond to the emergency.
Amended at 12 Ok Reg 2847,
						eff 7-15-95; Amended at 24 Ok Reg 2741, eff
						8-11-07
Oklahoma Administrative Code › Title 475 - Oklahoma State Bureau of Narcotics and Dangerous Drugs Control › Chapter 30 - Labeling Requirements › Section 475:30-1-4 - Manner of issuance of prescriptions

Current through Vol. 41, No. 20, July 1, 2024
(a) The practitioner shall sign a prescription in the same manner he/she would sign a check or legal document and shall also type, stamp, or print the practitioner's name on the face of each prescription. Where an oral order is not permitted or an electronic prescription is not utilized, prescriptions shall be written with ink. All written prescriptions shall be manually signed by the practitioner. The prescriptions may be prepared by an agent for the signature of a practitioner, but the prescribing practitioner is responsible in the event the prescription does not conform in all essential respects to the Uniform Controlled Dangerous Substances Act and this Chapter.
(b) A practitioner exempted from registration or registered in fee-exempt status with the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control (OBN), shall include on all prescriptions issued by him/her the hospital or institutional Federal Drug Enforcement Administration (DEA) registration number with the special internal code number assigned by the hospital or other institution; or include on all prescriptions he/she issues his/her personal DEA registration number. Such prescriptions issued by interns of a teaching hospital, if for outpatients, must be countersigned by a practitioner licensed by the practitioner's appropriate State of Oklahoma licensing board.
(c) A practitioner must state on a prescription for any controlled dangerous substance the name, address, and DEA registration number of the practitioner; the date of delivery of the prescription; the name, dosage, and strength per dosage unit of the controlled dangerous substance; the name and address of the patient, or if it is a veterinary prescription, the species of the animal and the name and address of the owner; the directions for use and any cautionary statements required; and if allowable, the number of times to be refilled.
(1) The face of a prescription must not be materially altered; if an error is made in filling out the prescription, a new prescription must be issued by the prescribing practitioner.
(A) A pharmacist may add to the prescription the patient's address or age, the prescribing practitioner's DEA registration number, or the generic drug name if used.
(B) After confirming with the prescribing practitioner, the pharmacist may add information indicating the strength, whether tablet or capsule form, and whether it is compounded if such additions would not materially alter the prescription.
(C) If omitted, the directions (Sig) or the quantity, may be added by the pharmacist after confirming with the prescribing practitioner.
(D) Documentation of contacting the prescribing practitioner will be noted on the back of the prescription regarding (B) and (C) above.
Oklahoma Administrative Code › Title 475 - Oklahoma State Bureau of Narcotics and Dangerous Drugs Control › Chapter 30 - Labeling Requirements › Section 475:30-1-4 - Manner of issuance of prescriptions

Current through Vol. 41, No. 20, July 1, 2024
(a) The practitioner shall sign a prescription in the same manner he/she would sign a check or legal document and shall also type, stamp, or print the practitioner's name on the face of each prescription. Where an oral order is not permitted or an electronic prescription is not utilized, prescriptions shall be written with ink. All written prescriptions shall be manually signed by the practitioner. The prescriptions may be prepared by an agent for the signature of a practitioner, but the prescribing practitioner is responsible in the event the prescription does not conform in all essential respects to the Uniform Controlled Dangerous Substances Act and this Chapter.
(b) A resident or staff practitioner, an intern of a teaching hospital, or a limited institutional practitioner of a federal, state, or local government hospital or institution, exempted from registration or registered in fee-exempt status with the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control (OBN), shall include on all prescriptions issued by him/her the hospital or institutional Federal Drug Enforcement Administration (DEA) registration number with the special internal code number assigned by the hospital or other institution; or include on all prescriptions he/she issues his/her personal DEA registration number. Such prescriptions issued by interns of a teaching hospital, if for outpatients, must be countersigned by a practitioner licensed by the practitioner's appropriate State of Oklahoma licensing board.
(c) A practitioner must state on a prescription for any controlled dangerous substance the name, address, and DEA registration number of the practitioner; the date of delivery of the prescription; the name, dosage, and strength per dosage unit of the controlled dangerous substance; the name and address of the patient, or if it is a veterinary prescription, the species of the animal and the name and address of the owner; the directions for use and any cautionary statements required; and if allowable, the number of times to be refilled.
(1) The face of a prescription must not be materially altered; if an error is made in filling out the prescription, a new prescription must be issued by the prescribing practitioner.
(A) A pharmacist may add to the prescription the patient's address or age, the prescribing practitioner's DEA registration number, or the generic drug name if used.
(B) After confirming with the prescribing practitioner, the pharmacist may add information indicating the strength, whether tablet or capsule form, and whether it is compounded if such additions would not materially alter the prescription.
(C) If omitted, the directions (Sig) or the quantity, may be added by the pharmacist after confirming with the prescribing practitioner.
(D) Documentation of contacting the prescribing practitioner will be noted on the back of the prescription regarding (B) and (C) above.
Oklahoma Administrative Code › Title 475 - Oklahoma State Bureau of Narcotics and Dangerous Drugs Control › Chapter 30 - Labeling Requirements › Section 475:30-1-5 - Dispensing of narcotic drugs during scientific research

Current through Vol. 41, No. 20, July 1, 2024
(a) The administering or dispensing directly
					(but not prescribing) of narcotic drugs in any schedule to a narcotic drug
					dependent person for the purpose of continuing his/her dependence upon such
					drugs in the course of conducting an authorized clinical scientific research in
					the development of a narcotic addict rehabilitation program shall be deemed to
					be within the meaning of the term "in the course of his/her professional
					practice or research"; PROVIDED that approval is obtained prior to the
					initiation of such a program by submission of a protocol submitted to the OBN
					and the State of Oklahoma Department of Mental Health and Substance Abuse
					Services. It will be reviewed by the State of Oklahoma Department of Mental
					Health and Substance Abuse Services for scientific merit and qualifications and
					by the OBN for controlled dangerous substance requirements as provided by the
					Uniform Controlled Dangerous Substances Act and this Chapter.
(b) Nothing in this Title shall prohibit a
					physician who is not specifically registered to conduct a narcotic treatment
					program from administering (but not prescribing) narcotic drugs to a person for
					the purpose of relieving acute withdrawal symptoms, when necessary, while
					arrangements are being made for referral for treatment. Not more than one (1)
					day's medication may be administered to the person or for the person's use at
					one time. Such emergency treatment may be carried out for not more than three
					(3) days and may not be renewed or extended.
Oklahoma Administrative Code › Title 475 - Oklahoma State Bureau of Narcotics and Dangerous Drugs Control › Chapter 30 - Labeling Requirements › Section 475:30-1-7 - Partial filling of Schedule II prescriptions

Current through Vol. 41, No. 20, July 1, 2024
(a) The partial filling of a prescription for a controlled dangerous substance listed in Schedule II is permissible if the pharmacy is unable to supply the full quantity called for on the prescription, or where the partial fill is requested by the patient or the practitioner that wrote the prescription. A notation of the quantity supplied on the face of the prescription (or written record of the emergency oral prescription) is required. Except as otherwise prohibited by law or rule, if the remaining portion of the prescription is going to be filled, it shall be filled not later than thirty (30) days after the earliest date on which a pharmacy may fill the prescription; however, in the case of emergency oral prescriptions, the remaining portion of a partially filled prescription shall be filled not later than seventy-two (72) hours after the earliest date on which a pharmacy may fill the prescription.
(b) For each partial filling, the dispensing pharmacist shall record on the back of the prescription (or on another appropriate record, uniformly maintained, and readily retrievable) the date of the partial filling, quantity dispensed, remaining quantity authorized to be dispensed, and the identification of the dispensing pharmacist. Prior to any subsequent partial filling, the pharmacist is to determine that the additional partial filling is necessary. The total quantity of Schedule II controlled dangerous substances dispensed in all partial fillings must not exceed the total quantity prescribed. Schedule II prescriptions for patients in a LTCF or patients with a medical diagnosis documenting a terminal illness shall be valid for a period not to exceed 60 days from the issue date unless sooner terminated by the discontinuance of medication.
Amended at 12 Ok Reg 2847,
						eff 7-15-95; Amended at 24 Ok Reg 2741, eff
						8-11-07
Oklahoma Administrative Code › Title 475 - Oklahoma State Bureau of Narcotics and Dangerous Drugs Control › Chapter 30 - Labeling Requirements › Section 475:30-1-8 - Labeling of substances for institutionalized persons [REVOKED]

Current through Vol. 41, No. 20, July 1, 2024
Revoked at 24 Ok Reg 1741,
						eff 8-11-07
Oklahoma Administrative Code › Title 475 - Oklahoma State Bureau of Narcotics and Dangerous Drugs Control › Chapter 30 - Labeling Requirements › Section 475:30-1-9 - Filling of emergency prescriptions [REVOKED]

Current through Vol. 41, No. 20, July 1, 2024
Revoked at 24 Ok Reg 1741,
						eff 8-11-07
Oklahoma Administrative Code › Title 475 - Oklahoma State Bureau of Narcotics and Dangerous Drugs Control › Chapter 30 - Labeling Requirements › Section 475:30-1-10 - Requirements of prescriptions for controlled dangerous substances listed in Schedules III and IV

Current through Vol. 41, No. 20, July 1, 2024
(a) A pharmacy may dispense controlled dangerous substances listed in Schedules III or IV only pursuant to either a prescription signed by a registered or otherwise authorized individual practitioner, except as otherwise prohibited by law or rule, an oral prescription made by a prescribing registered or otherwise authorized individual practitioner and promptly reduced to writing by the pharmacist, containing all the information required by Title 63 Okl.St.Ann.  §§
								2-309  and  2-314, and  this Chapter, or pursuant to an electronic prescription in compliance with the terms of  21 CFR §§ 1311  et. seq. Computer labels meeting these requirements are acceptable.
(b) A registered or otherwise authorized individual practitioner may administer or dispense directly a controlled dangerous substance listed in Schedule III or IV in the course of his/her professional practice without a prescription, subject to 475:30-1-5.
(c) An institutional practitioner limited in practice by the individual's appropriate State of Oklahoma professional licensing board, other than those registered as fee-exempt by the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control, may administer or dispense directly (but not prescribe) a controlled dangerous substance listed in Schedule III or IV pursuant to a prescription signed by the "Limited Institutional Practitioner's" supervising chief medical practitioner, or, except as otherwise prohibited by law or rule, pursuant to oral prescription made by the "Limited Institutional Practitioner's" supervising chief medical practitioner and promptly reduced to writing by the pharmacist containing all information required by 475:30-1-4, except for the signature of the "Limited Institutional Practitioner's" supervising chief medical practitioner or pursuant to an order for medication made by an individual supervising chief medical practitioner which is dispensed for immediate administration to the ultimate user, subject to 475:30-1-5.
Amended at 12 Ok Reg 2847,
						eff 7-15-95; Amended at 29 Ok Reg 1320, eff
						6-25-12
Oklahoma Administrative Code › Title 475 - Oklahoma State Bureau of Narcotics and Dangerous Drugs Control › Chapter 30 - Labeling Requirements › Section 475:30-1-11 - Refilling of prescriptions; issuance of multiple prescriptions

Current through Vol. 41, No. 20, July 1, 2024
(a) The
					refilling of a prescription for a controlled dangerous substance listed in
					Schedule II is prohibited.
(b)
					Except as prohibited by law or rule, an individual practitioner may issue
					multiple prescriptions authorizing the patient to receive a total of up to a
					90-day supply of a Schedule II controlled dangerous substance provided the
					following conditions are met:
(1) Each
					separate prescription is issued for a legitimate medical purpose by an
					individual practitioner acting in the usual course of professional practice;
(2) The individual practitioner
					provides written instructions on each prescription (other than the first
					prescription, if the prescribing practitioner intends for that prescription to
					be filled immediately) indicating the earliest date on which a pharmacy may
					fill each prescription;
(3) The
					individual practitioner concludes that providing the patient with multiple
					prescriptions in this manner does not create an undue risk of diversion or
					abuse; and,
(4) The individual
					practitioner complies fully with all other applicable requirements.
Oklahoma Administrative Code › Title 475 - Oklahoma State Bureau of Narcotics and Dangerous Drugs Control › Chapter 30 - Labeling Requirements › Section 475:30-1-12 - Partial filling of Schedules III, IV, and V prescriptions

Current through Vol. 41, No. 20, July 1, 2024
The partial filling of a prescription for a controlled
						dangerous substance listed in Schedules III, IV, or V is permissible; PROVIDED
						that:
(1) Each partial filling is
					recorded in the same manner as a refilling.
(2) The total quantity dispensed in all
					partial fillings does not exceed the total quantity prescribed.
(3) No dispensing occurs six (6) months after
					the date on which the prescription was issued.
Oklahoma Administrative Code › Title 475 - Oklahoma State Bureau of Narcotics and Dangerous Drugs Control › Chapter 30 - Labeling Requirements › Section 475:30-1-13 - Requirements of prescriptions for controlled dangerous substances listed in Schedule V

Current through Vol. 41, No. 20, July 1, 2024
(a) A pharmacist
					of a registered or otherwise authorized pharmacy may dispense directly a
					controlled dangerous substance listed in Schedule V pursuant to a prescription
					as required for controlled dangerous substances listed in Schedules III and IV.
					A prescription for a controlled dangerous substance listed in Schedule V may be
					refilled only the number of times expressly authorized by the prescribing
					registered individual practitioner on the face of the prescription, and such
					prescription may not be refilled more than six (6) months after the date of
					issuance. If no such authorization is given, the prescription may not be
					refilled. A pharmacist dispensing such substance pursuant to a prescription
					shall label the substance and file the prescription.
(b) A registered individual practitioner may
					administer or dispense directly a controlled dangerous substance listed in
					Schedule V, in the course of his/her professional practice, without a
					prescription.
(c) An institutional
					physician limited in practice by the individual's appropriate State of Oklahoma
					professional licensing board, other than those registered as fee-exempt with
					the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control, may
					administer or dispense directly (but not prescribe) a controlled dangerous
					substance listed in Schedule V only pursuant to a written prescription signed
					by the "Limited Institutional Practitioner's" supervising chief medical
					practitioner, or pursuant to an oral prescription made by a "Limited
					Institutional Practitioner's" supervising chief medical practitioner and
					promptly reduced to writing by the pharmacist (containing all information
					required in
					475:30-1-4,
					except for the signature of the "Limited Institutional Practitioner's"
					supervising practitioner), or pursuant to an order for medication made by a
					"Limited Institutional Practitioner's" supervising chief medical practitioner
					which is dispensed for immediate administration to the ultimate user.
Amended at 12 Ok Reg 2847,
						eff 7-15-95
Oklahoma Administrative Code › Title 475 - Oklahoma State Bureau of Narcotics and Dangerous Drugs Control › Chapter 30 - Labeling Requirements › Section 475:30-1-14 - Dispensing, prescribing, administering, or distributing without prescription

Current through Vol. 41, No. 20, July 1, 2024
A controlled dangerous substance listed in Schedule V which is not a prescription drug as determined by the Oklahoma State Board of Pharmacy and/or the Federal Food and Drug Administration, may be dispensed by a pharmacy without a prescription to a purchaser at retail level; PROVIDED that:
(1) Such dispensing is made only by a pharmacist that has been licensed by the Oklahoma State Board of Pharmacy to dispense controlled dangerous substances and not by a non-pharmacist employee, even if under the supervision of a pharmacist (although after the pharmacist has fulfilled his/her professional and legal responsibilities set forth in this Section, the actual cash, credit transaction or delivery may be completed by a non-pharmacist).
(2) No person shall dispense, prescribe, administer or distribute to any one person, for the use of any one person or animal, any preparation(s) included in Title 63 Okl.St.Ann.  §
								2-313(B)(1),  when the dispensing, prescribing, administering or distributing person knows, or can by reasonable diligence ascertain, that such dispensing, prescribing, administering or distributing will provide the person to whom or for whose use, or the owner of the animal for the use of which, such preparation is prescribed, administered, dispensed or distributed, within any forty-eight (48) consecutive hours, with more than 320 milligrams of opium, or more than 40 milligrams of morphine or any of its salts, or more than 160 milligrams of codeine or any of its salts, or will provide such person or the owner of such animal, within forty-eight (48) consecutive hours, more than one preparation exempted by Title 63 Okl.St.Ann.  §
								2-313.
(3) Except as otherwise authorized by the Act, OAC 475:30-1-14 shall not apply to the following cases:
(A) Prescribing, administering, dispensing or selling at retail not more than one of any of the following medicinal preparations that contain in thirty (30) milliliters or if a solid or semi-solid preparation, in one (1) avoirdupois ounce:
(i) Not more than one hundred sixty (160) milligrams of opium.
(ii) Not more than twenty (20) milligrams of morphine or any of its salts.
(iii) Not more than eighty (80) milligrams of codeine or any of its salts.
Oklahoma Administrative Code › Title 475 - Oklahoma State Bureau of Narcotics and Dangerous Drugs Control › Chapter 30 - Labeling Requirements › Section 475:30-1-15 - Identification requirement

Current through Vol. 41, No. 20, July 1, 2024
Pharmacists are required to obtain valid identification as
						required by Title 63 §2-309C if they are unsure of the identity of a
						person picking up a prescription for any controlled dangerous
						substance.
Amended at 24 Ok Reg 1741,
						eff 8-11-07; Amended at 29 Ok Reg 1320, eff
						6-25-12
Oklahoma Administrative Code › Title 475 - Oklahoma State Bureau of Narcotics and Dangerous Drugs Control › Chapter 35 - Transfer and Disposal of Controlled Dangerous Drugs › Section 475:35-1-2 - Distribution by a registered practitioner or pharmacy to another registered practitioner or pharmacy

Current through Vol. 41, No. 20, July 1, 2024
(a) A
					practitioner or pharmacy who is registered to dispense a controlled dangerous
					substance may distribute (without being registered to distribute) a quantity of
					such substance to another registered practitioner or pharmacy for the purpose
					of general dispensing by the practitioner or pharmacy to his/her or its
					patients; PROVIDED that:
(1) The practitioner
					or pharmacy to whom the controlled dangerous substance is to be distributed is
					registered under the Uniform Controlled Dangerous Substances Act to dispense
					that controlled dangerous substance.
(2) The distribution is recorded by the
					distributing practitioner or pharmacy and by the receiving practitioner or
					pharmacy in accordance with Chapter 25 of this Title. If the substance is
					listed in Schedule I or II, an order form is used, as required by Title 21 Code
					of Federal Regulations, §1305, and pursuant to Title 63 Okl.St.Ann.
					§2-308 .
(3) The total number
					of dosage units of all controlled dangerous substances distributed by the
					practitioner pursuant to this Section during the 12-month period in which the
					practitioner or pharmacy is registered to dispense does not exceed five percent
					(5%) of the total number of dosage units of all controlled dangerous substances
					distributed and dispensed by the practitioner during the 12-month
					period.
Oklahoma Administrative Code › Title 475 - Oklahoma State Bureau of Narcotics and Dangerous Drugs Control › Chapter 35 - Transfer and Disposal of Controlled Dangerous Drugs › Section 475:35-1-3 - Distribution upon discontinuance or transfer of business

Current through Vol. 41, No. 20, July 1, 2024
(a) Any registrant desiring to discontinue business activities altogether or with respect to controlled dangerous substances (without transferring such business activities to another person) shall notify the OBN. Any controlled dangerous substances in his/her possession shall be disposed of in accordance with Title 21 Code of Federal Regulations, part 1317. Schedule I medical marijuana shall be disposed pursuant to standards set forth in 63 Okla.St.Ann.  §
								429.
(b) Any registrant desiring to discontinue business activities altogether or with respect to controlled dangerous substances (by transferring such business activities to another person) shall submit to the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control (OBN) at least fourteen (14) days in advance of the date of the proposed transfer (unless the Director waives this time limitation in individual instances), the following information:
(1) The name, address, registration number, and authorized business activity of the registrant discontinuing the business (registrant-transferor).
(2) The name, address, registration number, and authorized business activity of the person acquiring the business (registrant-transferee).
(3) Whether the business activities will be continued at the location registered by the person discontinuing the business or moved to another location (if the latter, the address of the new location should be listed).
(4) Whether the registrant-transferor has a quota to manufacture or procure any controlled dangerous substance listed in Schedule I or II (if so, the basic class or classes of the substance should be indicated).
(5) The date on which the transfer of controlled dangerous substances will occur.
Oklahoma Administrative Code › Title 475 - Oklahoma State Bureau of Narcotics and Dangerous Drugs Control › Chapter 35 - Transfer and Disposal of Controlled Dangerous Drugs › Section 475:35-1-3 - Distribution upon discontinuance or transfer of business

Current through Vol. 41, No. 20, July 1, 2024
(a) Any registrant desiring to discontinue business activities altogether or with respect to controlled dangerous substances (without transferring such business activities to another person) shall return for cancellation of his/her Certificate of Registration. Any controlled dangerous substances in his/her possession shall be disposed of in accordance with Title 21 Code of Federal Regulations, part 1317. Schedule I medical marijuana shall be disposed pursuant to standards set forth in 63 Okla.St.Ann.  § 429.
(b) Any registrant desiring to discontinue business activities altogether or with respect to controlled dangerous substances (by transferring such business activities to another person) shall submit in person or by registered or certified mail, return receipt requested, to the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control (OBN) at least fourteen (14) days in advance of the date of the proposed transfer (unless the Director waives this time limitation in individual instances), the following information:
(1) The name, address, registration number, and authorized business activity of the registrant discontinuing the business (registrant-transferor).
(2) The name, address, registration number, and authorized business activity of the person acquiring the business (registrant-transferee).
(3) Whether the business activities will be continued at the location registered by the person discontinuing the business or moved to another location (if the latter, the address of the new location should be listed).
(4) Whether the registrant-transferor has a quota to manufacture or procure any controlled dangerous substance listed in Schedule I or II (if so, the basic class or classes of the substance should be indicated).
(5) The date on which the transfer of controlled dangerous substances will occur.
Oklahoma Administrative Code › Title 475 - Oklahoma State Bureau of Narcotics and Dangerous Drugs Control › Chapter 35 - Transfer and Disposal of Controlled Dangerous Drugs › Section 475:35-1-4 - Procedure for disposing of controlled dangerous substances

Current through Vol. 41, No. 20, July 1, 2024
Any registrant in possession of any controlled dangerous substances and desiring or required to dispose of such substances shall do so according to the provisions of Title 63 Okl.St.Ann.  §
								2-315  and  Title 21 of the Code of Federal Regulations, part 1317, except Schedule I medical marijuana shall be disposed pursuant to standards set forth in 63 Okla.St.Ann.  § 429.
Oklahoma Administrative Code › Title 475 - Oklahoma State Bureau of Narcotics and Dangerous Drugs Control › Chapter 35 - Transfer and Disposal of Controlled Dangerous Drugs › Section 475:35-1-5 - Procedure for disposing of controlled dangerous substances in bankruptcy proceeding

Current through Vol. 41, No. 20, July 1, 2024
At no time shall a representative who is not duly registered
						with the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control be in
						possession of any controlled dangerous substances awarded out of a bankruptcy
						proceeding.
Amended at 24 Ok Reg 2745,
						eff 8-11-07
Oklahoma Administrative Code › Title 475 - Oklahoma State Bureau of Narcotics and Dangerous Drugs Control › Chapter 40 - Enforcement and Administrative Inspections › Section 475:40-1-1 - Purpose

Current through Vol. 41, No. 20, July 1, 2024
The rules of this Chapter set out the authority for
						administrative inspections of OBN registrants to validate compliance with rules
						and statutes.
Oklahoma Administrative Code › Title 475 - Oklahoma State Bureau of Narcotics and Dangerous Drugs Control › Chapter 40 - Enforcement and Administrative Inspections › Section 475:40-1-2 - Authority to make inspections

Current through Vol. 41, No. 20, July 1, 2024
Administrative inspections of OBN registrants shall include, but not be limited to, the following:
(1) Inspecting, copying, and verifying the correctness of records, reports, or other documents required to be kept or made, including, but not limited to, inventory, patient records, and other records required to be kept pursuant to the Uniform Controlled Dangerous Substances Act, this Title, the Code of Federal Regulations governing controlled dangerous substances, or OMMA; order form records required to be kept pursuant to Title 63 Okl.St.Ann.  §
								2-308  and  other applicable state statutes and rules; prescriptions and distribution records required to be kept pursuant to Title 63 Okl.St.Ann.  §
								2-307  and  other applicable state statutes and rules; shipping records identifying the name of each carrier used; and the date and quantity of each storage.
(2) Inspecting within reasonable limits and in a reasonable manner all pertinent equipment, finished and unfinished controlled dangerous substances, and other substances or materials, containers, and labeling found at the controlled premises relating to the Uniform Controlled Dangerous Substances Act and this Title.
(3) Making a physical inventory of all controlled dangerous substances on hand at the premises.
(4) Collecting samples of controlled dangerous substances or precursors (in the event any samples are collected during an inspection, the peace officer or officer so authorized shall issue a receipt for such samples to the owner, operator or agent in charge of the premises).
(5) Inspecting within reasonable limits and in a reasonable manner records containing the contact information all employees, agents, contractors, or subcontractors to include the name, address, and phone number of each.
Oklahoma Administrative Code › Title 475 - Oklahoma State Bureau of Narcotics and Dangerous Drugs Control › Chapter 40 - Enforcement and Administrative Inspections › Section 475:40-1-2 - Authority to make inspections

Current through Vol. 41, No. 20, July 1, 2024
Administrative inspections of OBN registrants shall include,
						but not be limited to, the following:
(1) Inspecting, copying, and verifying the
					correctness of records, reports, or other documents required to be kept or
					made, including, but not limited to, inventory, patient records, and other
					records required to be kept pursuant to the Uniform Controlled Dangerous
					Substances Act, this Title, the Code of Federal Regulations governing
					controlled dangerous substances, or OAC 310:681-5-6; order form records
					required to be kept pursuant to Title 63 Okl.St.Ann. §
								2-308 and
					other applicable state statutes and rules; prescriptions and distribution
					records required to be kept pursuant to Title 63 Okl.St.Ann. §
								2-307 and
					other applicable state statutes and rules; shipping records identifying the
					name of each carrier used; and the date and quantity of each storage.
(2) Inspecting within reasonable limits and
					in a reasonable manner all pertinent equipment, finished and unfinished
					controlled dangerous substances, and other substances or materials, containers,
					and labeling found at the controlled premises relating to the Uniform
					Controlled Dangerous Substances Act and this Title.
(3) Making a physical inventory of all
					controlled dangerous substances on hand at the premises.
(4) Collecting samples of controlled
					dangerous substances or precursors (in the event any samples are collected
					during an inspection, the peace officer or officer so authorized shall issue a
					receipt for such samples to the owner, operator or agent in charge of the
					premises).
Amended at 24 Ok Reg 2746,
						eff 8-11-07
Oklahoma Administrative Code › Title 475 - Oklahoma State Bureau of Narcotics and Dangerous Drugs Control › Chapter 40 - Enforcement and Administrative Inspections › Section 475:40-1-3 - Entry

Current through Vol. 41, No. 20, July 1, 2024
A peace officer of the State of Oklahoma, upon stating his/her
						purpose and presenting to the owner, operator or agent in charge of the
						premises to be inspected his/her appropriate credentials, shall have the right
						to enter such premises and conduct inspections at reasonable times and in a
						reasonable manner.
Oklahoma Administrative Code › Title 475 - Oklahoma State Bureau of Narcotics and Dangerous Drugs Control › Chapter 45 - Oklahoma Control Reporting Requirements › Section 475:45-1-1 - Purpose

Current through Vol. 41, No. 20, July 1, 2024
The rules of this Chapter delineate the requirement of
						pharmacies or dispensing (but not administering) practitioners to report
						certain information upon filling any prescription for any controlled dangerous
						substance in schedules II, III, IV or V.
Added at 18 Ok Reg 2218,
						eff 6-11-01; Amended at 24 Ok Reg 2747, eff 8-11-07; Amended at 29 Ok Reg 1323,
						eff 6-25-12
Oklahoma Administrative Code › Title 475 - Oklahoma State Bureau of Narcotics and Dangerous Drugs Control › Chapter 45 - Oklahoma Control Reporting Requirements › Section 475:45-1-2 - Required reporting of certain information

Current through Vol. 41, No. 20, July 1, 2024
(a) Every pharmacy or dispensing practitioner filling any Schedule II, III, IV, or V prescriptions must report the following information to a central repository maintained by the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control (OBN). The information must include, but not be limited to, the following:
(1) Recipient's name;
(2) Recipient's address;
(3) Recipient's date of birth;
(4) Recipient's identification number;
(5) National Drug Code number of the substance dispensed;
(6) Date of the dispensation;
(7) Quantity of the substance dispensed;
(8) Prescriber's U.S. Drug Enforcement Administration registration number;
(9) Dispenser's U.S. Drug Enforcement Administration registration number and location; and
(10) Other information as required by the most recent version of the American Society for Automation in Pharmacy's (ASA) Telecommunications Format for Controlled Substances.
Oklahoma Administrative Code › Title 475 - Oklahoma State Bureau of Narcotics and Dangerous Drugs Control › Chapter 45 - Oklahoma Control Reporting Requirements › Section 475:45-1-3 - Method of reporting

Current through Vol. 41, No. 20, July 1, 2024
Each pharmacy or dispensing practitioner must transmit the
						information required in
						475:45-1-2
						in the following manner: on an electronic device which is compatible with the
						receiving device of the central repository.
Added at 18 Ok Reg 2218,
						eff 6-11-01; Amended at 24 Ok Reg 2747, eff 8-11-07; Amended at 29 Ok Reg 1323,
						eff 6-25-12
Oklahoma Administrative Code › Title 475 - Oklahoma State Bureau of Narcotics and Dangerous Drugs Control › Chapter 45 - Oklahoma Control Reporting Requirements › Section 475:45-1-4 - Waiver of electronic submissions

Current through Vol. 41, No. 20, July 1, 2024
(a) The Director of the OBN may waive the
					requirement to submit prescription data in an electronic format, and allow a
					pharmacy filling a prescription of a Schedule II, III, IV, or V controlled
					dangerous substance to submit prescription data in a paper format if the
					dispenser has an appropriate hardship.
(b) A formal request for this waiver must be
					made in writing to the OBN and must clearly state (1) the nature and extent of
					the hardship; and, (2) a proposed time-line for the waiver.
(c) Any such hardship granted by the Director
					of OBN will be reviewed every thirty (30) days following the granting of a
					waiver to determine whether or not the hardship will be extended.
Added at 18 Ok Reg 2218,
						eff 6-11-01; Amended at 24 Ok Reg 2747, eff 8-11-07; Amended at 29 Ok Reg 1323,
						eff 6-25-12
Oklahoma Administrative Code › Title 475 - Oklahoma State Bureau of Narcotics and Dangerous Drugs Control › Chapter 45 - Oklahoma Control Reporting Requirements › Section 475:45-1-5 - Time limit for reporting

Current through Vol. 41, No. 20, July 1, 2024
The information required by this section must be reported to
						the central repository within five (5) minutes of the time that the controlled
						dangerous substance was dispensed.
Added at 18 Ok Reg 2218,
						eff 6-11-01; Amended at 24 Ok Reg 2747, eff 8-11-07; Amended at 29 Ok Reg 1323,
						eff 6-25-12
Oklahoma Administrative Code › Title 475 - Oklahoma State Bureau of Narcotics and Dangerous Drugs Control › Chapter 45 - Oklahoma Control Reporting Requirements › Section 475:45-1-6 - Failure to report

Current through Vol. 41, No. 20, July 1, 2024
Failure to accurately report the required information, or correct inaccuracies within reported information, according to the rules set forth in this Chapter may result in administrative action against the registration of the pharmacy or dispensing practitioner, including, but not limited to, fines not to exceed Five Thousand Dollars ($5000) per violation.